<DOC>
	<DOCNO>NCT02251210</DOCNO>
	<brief_summary>To investigate efficacy safety 3 dos BIIL 284 BS active rheumatoid arthritis ( RA ) determine dose positive efficacy / safety ratio . Pharmacokinetic profile also obtain .</brief_summary>
	<brief_title>Efficacy Safety BIIL 284 BS Adult Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients &gt; =18 &lt; = 70 year age Patients suffer rheumatoid arthritis define American Rheumatism Association ( ARA ) criterion revise 1987 date diagnosis &gt; = 6 month . At least 4 follow 7 criterion must present : Morning stiffness around joint last least 1 hour maximal improvement least 6 week Arthritis ( soft tissue thicken fluid bony overgrowth alone ) least 3 joint area least 6 week Arthritis hand joint ( least one area swell wrist , metacarpophalangeal ( MCP ) proximal interphalangeal ( PIP ) joint ) least 6 week Symmetrical arthritis ( observed physician ) simultaneous involvement joint side body least 6 week Rheumatoid nodule ( observed physician ) bony prominence extensor surface juxtaarticular region Serum rheumatoid factor positive Xray change typical rheumatoid arthritis ( erosion unequivocal bony decalcification localize marked adjacent involved joint ) Patients belong RA functional class I , II III Active RA define visit 2 : Swollen joint count least 6 ( 28 joint examine ) Tender joint count least 8 ( 28 joint examine ) Patients must fulfil 2 3 follow criterion : Patient 's assessment pain ( VAS ) &gt; = 40 mm Investigator 's global assessment disease activity VAS &gt; = 40 mm ESR &gt; = 28 mm/h CRP &gt; = 20 mg/L Patient 's write informed consent obtain Visit 1 ( screen ) enrolment study Patient present history inflammatory rheumatic disease RA ( e.g . : mixed connective tissue disease , systemic lupus erythematosus , seronegative spondyloarthropathy ) Patients fail 3 different diseasemodifying antirheumatic drug ( DMARDs ) therapies previously due lack efficacy ( case combine therapy DMARDs use count one ) Patients disease could interfere evaluation efficacy safety Patients treatment DMARDs / slowacting antirheumatic drug ( SAARDs ) period specify : 4 week V2 : Methotrexate , parenteral/oral gold , Dpenicillamine , Sulphasalazine , antimalarial ( e.g . : Chloroquine/Hydroxychloroquine ) , Azathioprine , Cyclosporine A , Alkylating agent ( e.g . : Cyclophosphamide / Chlorambucil ) , Minocycline , Etanercept ( Enbrel® ) , Leflunomide ( washout Colestyramine do leflunomide discontinuation ) 3 month Visit 2 : Leflunomide wash colestyramine do leflunomide discontinuation , Infliximab ( Remicade® ) , biological compound . Patient treatment oral corticosteroid dose high 10 mg/day 0.2 mg/Kg/day ( prednisone equivalent ) whichever low , 4 week prior Visit 2 , change treatment oral corticosteroid 4 week prior Visit 2 intend change trial Patients treatment parenteral ( intravenous , intramuscular intraarticular ) treatment corticosteroid 4 week prior Visit 2 intend use trial . Change treatment nonsteroidal antiinflammatory drug ( NSAIDs ) 2 week prior Visit 2 intend change trial . Synovectomy , and/or surgical treatment RA previous 3 month prior visit 2 intend indication trial . Synoviorthesis previous 4 week prior Visit 2 intend indication trial . Patients treatment leukotriene inhibitor montelukast zafirlukast 4 week prior Visit 2 intend use trial . Initiation physiotherapy 2 week V2 , intend change trial Patients history cardiovascular , renal , neurologic , psychiatric , liver , gastrointestinal ( include lactose intolerance ) , immunologic endocrine dysfunction clinically significant . Patients know condition circumstance , would investigator 's opinion , prevents compliance completion study Patients history cancer within past 5 year , exclude treat basal cell carcinoma Patients chronic infection acute infection 4 week visit 1 Patients know positive serology hepatitis B C Patients anticoagulant treatment ( i.e . dicumarol derivative , warfarin ) Any follow abnormal laboratory parameter Visit 2 : Impaired hepatic function , define serum level either Aspartate Aminotransferase ( AST ) ( SGOT ) , Alanine Aminotransferase ( ALT ) ( SGPT ) , alkaline phosphatase bilirubin &gt; 2 x upper limit normal ( ULN ) Impaired renal function , define serum creatinine &gt; 133 mmol/L ( 1.5 mg/dl ) Hemoglobin value &lt; 10 g/dl White blood cell count &lt; = 3.500 cells/mm3 Platelet count le 120.000/mm3 Severe hypoproteinemia ( e.g . case severe liver disease nephrotic syndrome ) albumin &lt; 3.0 g/dl Patients abnormal , clinically relevant laboratory value relate RA Patients participate another clinical trial 3 month prior visit 2 Previous participation randomise period study Patients significant history and/or active alcohol drug abuse Significant define opinion investigator may either put patient risk participation study may influence result study patient 's ability participate study Pregnancy ( excluded pregnancy test visit 1 ) breast feeding , sexually active woman childbearing potential use medically approve method contraception ( i.e . oral contraceptive , intrauterine device , doublebarrier ) least one month throughout study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>